TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19697825

Group type: EXPERIMENTAL
Intervention: Patient-controlled continuous epidural analgesia (PCEA) with 0.125% bupivacaine and 0.2 microg kg(‐1) fentanyl (basic infusion 1 mL h(‐1), bolus 4 mL, lock‐out time 15 min)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Remifentanil PCA (0.2 microg kg(‐1) bolus doses, without basic infusion, lock‐out time 2 min)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Remifentanil PCA
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: PCEA
Number of subjects: 52
Study: 17896891

Group type: EXPERIMENTAL
Intervention: Rifaximin 200 mg every 8 hours for 7 days
Number of subjects: 27

Group type: COMPARATOR
Intervention: Single-dose intravenous midazolam 2 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Single-dose oral midazolam 6 mg
Number of subjects: 27
Study: 15111537

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11927450

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg morphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 60
Study: 9652875

Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg/d for 1 year
Number of subjects: 2138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2138
Study: 7661159

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d. with 1 g amoxicillin b.i.d.
Number of subjects: 52

Group type: COMPARATOR
Intervention: High dose ranitidine (900 and 1800 mg) plus sodium bicarbonate tablets 650 t.i.d. with 1 g amoxicillin b.i.d.
Number of subjects: 52
Study: 2475701

Group type: EXPERIMENTAL
Intervention: Felodipine ER 20 mg
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Felodipine ER 10 mg
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 21788

Group type: EXPERIMENTAL
Intervention: Lidocaine solution with adrenaline plus Betadrenol (beta-receptor blocker)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lidocaine solution with adrenaline
Number of subjects: 0
Study: 30333221

Group type: EXPERIMENTAL
Intervention: Decision Support and Navigation Intervention (DSNI) Group
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard Intervention (SI) Group
Number of subjects: 400
Study: 28342739

Group type: EXPERIMENTAL
Intervention: Supervised physical therapy (PT)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Home exercise program (HEP)
Number of subjects: 74
Study: 26260318

Group type: EXPERIMENTAL
Intervention: Web-based computer tailored intervention (Kanker Nazorg Wijzer) providing psychosocial and lifestyle support
Number of subjects: 462

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 462
Study: 24151273

Group type: EXPERIMENTAL
Intervention: Low-dose radial extracorporeal shock-wave therapy (rESWT) - three sessions at an interval of 10 to 14 days, 2000 pulses, 0.11 mJ/mm², 8 Hz
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 82
Study: 21883902

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Cyclosporine A (CsA)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Subclinical inflammation (SCI)
Number of subjects: 121
Study: 19109542

Group type: EXPERIMENTAL
Intervention: mCIT + mental practice
Number of subjects: 10

Group type: COMPARATOR
Intervention: mCIT only
Number of subjects: 10
Study: 17967230

Group type: EXPERIMENTAL
Intervention: Trimetazidine (loading dose of 60 mg followed by 20 mg 3 times daily for 2 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 15133344

Group type: EXPERIMENTAL
Intervention: OT+PR
Number of subjects: 71

Group type: COMPARATOR
Intervention: PR
Number of subjects: 71
Study: 11240234

Group type: EXPERIMENTAL
Intervention: Adjuvant hormone therapy (goserelin)
Number of subjects: 945

Group type: COMPARATOR
Intervention: Radiation only
Number of subjects: 945
Study: 9469326

Group type: EXPERIMENTAL
Intervention: Low-dose EPO (2,000 U subcutaneously thrice weekly)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-dose EPO (10,000 U subcutaneously thrice weekly)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Patients not treated with chemotherapy (control group)
Number of subjects: 100
Study: 8553821

Group type: EXPERIMENTAL
Intervention: Air‐Stirrup ankle brace
Number of subjects: 73

Group type: COMPARATOR
Intervention: Compression bandage
Number of subjects: 73
Study: 1967227

Group type: EXPERIMENTAL
Intervention: Esmolol 80 mg bolus followed by 24 mg.min‐1 infusion
Number of subjects: 17

Group type: COMPARATOR
Intervention: No esmolol
Number of subjects: 17
Study: 361485

Group type: EXPERIMENTAL
Intervention: Sengstaken-Blakemore (SB) tube
Number of subjects: 79

Group type: COMPARATOR
Intervention: Linton-Nachlas (LN) tube
Number of subjects: 79
Study: 29972085

Group type: EXPERIMENTAL
Intervention: Randomised controlled trial of psychotherapy for treatment-resistant depression
Number of subjects: 37
Study: 31286931

Group type: EXPERIMENTAL
Intervention: Intervention group (youth-led education program)
Number of subjects: 512

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 512
Study: 29066863

Group type: EXPERIMENTAL
Intervention: 100 mg MB12066 twice daily for 8 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 25909794

Group type: EXPERIMENTAL
Intervention: ω‐3 polyunsaturated fatty acids (PUFAs), 1 capsule/day for three months
Number of subjects: 39

Group type: COMPARATOR
Intervention: Traditional hypoglycemic therapy
Number of subjects: 39
Study: 23707209

Group type: EXPERIMENTAL
Intervention: Herbal combination of Mentha longifolia, Cyperus rotundus, and Zingiber officinale
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mebeverine
Number of subjects: 40
Study: 21924093

Group type: EXPERIMENTAL
Intervention: Endoscopic vidian neurectomy (group A)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Partial inferior turbinectomy and/or septal-plasty (group B)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 191
Study: 19090588

Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (PTNS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study: 17881181

Group type: EXPERIMENTAL
Intervention: Flupentixol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Melitracen
Number of subjects: 0
Study: 15302727

Group type: EXPERIMENTAL
Intervention: Treprostinil (1.25 ng/kg/min, titrated to a maximum of 22.5 ng/kg/min)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 15848533

Group type: EXPERIMENTAL
Intervention: Early steroid withdrawal protocol using basiliximab, CsA (8 mg/kg), MMF (2000 mg), and methylprednisolone (500 mg) rapidly tapered and withdrawn at 14 POD
Number of subjects: 118

Group type: COMPARATOR
Intervention: Triple regimen consisting of CsA (same dose), MMF (same dose), and methylprednisolone (250 mg) tapered and continued
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Early steroid withdrawal protocol using basiliximab
Number of subjects: 118

Group type: COMPARATOR
Intervention: Triple regimen consisting of CsA, MMF, and methylprednisolone
Number of subjects: 118
Study: 11042565

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m² on Days 1, 8, and 15 plus cisplatin 80 mg/m² on Day 2 (arm A)
Number of subjects: 82
Study: 9493664

Group type: EXPERIMENTAL
Intervention: Comprehensive out-patient rehabilitation programme (physical training, occupational therapy, education, smoking cessation therapy) for 12 weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Comprehensive out-patient rehabilitation programme
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (not specified what the control intervention was)
Number of subjects: 47
Study: 8113483

Group type: EXPERIMENTAL
Intervention: Social relations intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nonintervention control group
Number of subjects: 52
Study: 3553220

Group type: EXPERIMENTAL
Intervention: Dopamine (4 micrograms/kg X min; 1 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GHRH (2 ng/kg X min; 2 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (0.15 M saline, 5 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GHRH (2 ng/kg X min; 2 h) plus dopamine (4 micrograms/kg X min; 1 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5 mg/dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2502583

Group type: EXPERIMENTAL
Intervention: 10 micrograms of rIFN‐gamma
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 100 micrograms of rIFN‐gamma
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 500 micrograms of rIFN‐gamma
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: All doses of rIFN‐gamma
Number of subjects: 16
Study: 31060619

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) plus usual care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 28402480

Group type: EXPERIMENTAL
Intervention: Experimental stress induction
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 120
Study: 26369412

Group type: EXPERIMENTAL
Intervention: PROMIS Anxiety
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: PROMIS Depression
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: PROMIS Pain Interference
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: PROMIS Physical Function
Number of subjects: 204
Study: 23240637

Group type: EXPERIMENTAL
Intervention: Breast cancer (BC)
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Breast cancer characteristics and treatment
Number of subjects: 1440

Group type: COMPARATOR
Intervention: Breast cancer-free women
Number of subjects: 1440
Study: 21284660

Group type: EXPERIMENTAL
Intervention: Topical slimming cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dietary advice
Number of subjects: 0
Study: 19631292

Group type: EXPERIMENTAL
Intervention: VSL#3 (3.6 x 10(12) CFU, twice daily for 12 weeks)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 17549330

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Coefficient (Coeff) in Norsk Grunntest for Afasi
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Amsterdam‐Nijmegen Everyday Language Test (ANELT)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Coefficient (Coeff)
Number of subjects: 208
Study: 15045624

Group type: EXPERIMENTAL
Intervention: Triamcinolone hexacetonide (THA) 20 mg (1 ml)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (MPA) 40 mg (1 ml)
Number of subjects: 57
Study: 11124794

Group type: EXPERIMENTAL
Intervention: Low dose ethinyloestradiol 50‐75 ng/kg/day, GH 28 IU/m(2) surface area/week as a daily injection
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Combination of ethinyloestradiol and GH
Number of subjects: 58

Group type: COMPARATOR
Intervention: Low dosage ethinyloestradiol
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: GH
Number of subjects: 58
Study: 10898562

Group type: EXPERIMENTAL
Intervention: School-based intervention promoting fruit and vegetable consumption (classroom, parent, and environmental components)
Number of subjects: 1698

Group type: COMPARATOR
Intervention: Control condition (no specific details provided)
Number of subjects: 1698
Study: 7857363

Group type: EXPERIMENTAL
Intervention: 1200 mg/day GEM
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2509590

Group type: EXPERIMENTAL
Intervention: AAT (aztreonam/amikacin/ticarcillin)
Number of subjects: 45

Group type: COMPARATOR
Intervention: LAT (latamoxef/amikacin/ticarcillin)
Number of subjects: 45
Study: 1098359

Group type: EXPERIMENTAL
Intervention: Piribedil + Levodopa
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Piribedil + Amantadine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31468636

Group type: EXPERIMENTAL
Intervention: NAR150 (150 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: NAR600 (600 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: NAR300 (300 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: NAR900 (900 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31044290

Group type: EXPERIMENTAL
Intervention: THC-dominant cannabis (125 mg, 11% THC; < 1% CBD)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: THC/CBD equivalent cannabis (125 mg, 11% THC, 11% CBD)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (< 1% THC/CBD)
Number of subjects: 14
Study: 28727817

Group type: EXPERIMENTAL
Intervention: Full dose DgDgM_M
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Full dose DgDgMM_M
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 3rd dose of MVA
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Co-expressed GM-CSF
Number of subjects: 48
Study: 25437881

Group type: EXPERIMENTAL
Intervention: Rosuvastatin calcium, 20mg daily
Number of subjects: 17802

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17802

Group type: EXPERIMENTAL
Intervention: Baseline hs-CRP levels
Number of subjects: 17802
Study: 23770109

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZ)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 21305544

Group type: EXPERIMENTAL
Intervention: Mindfulness strategy for managing cravings
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Suppression strategy for managing cravings
Number of subjects: 61
Study: 19356881

Group type: EXPERIMENTAL
Intervention: Patient Activation Measure (PAM)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: PAM
Number of subjects: 625
Study: 17316364

Group type: EXPERIMENTAL
Intervention: Nonplatinum therapy
Number of subjects: 161

Group type: COMPARATOR
Intervention: Platinum combination therapy
Number of subjects: 161
Study: 15016018

Group type: EXPERIMENTAL
Intervention: Ultrasonic instrumentation
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Hand curettes
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control untreated surfaces
Number of subjects: 25
Study: 11748394

Group type: EXPERIMENTAL
Intervention: Lidocaine with clonidine (10 microg/ml)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Plain lidocaine (1%)
Number of subjects: 7
Study: 9580757

Group type: EXPERIMENTAL
Intervention: Modified consent procedure (opting out)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional consent procedure (opting in)
Number of subjects: 44
Study: 8049313

Group type: EXPERIMENTAL
Intervention: tegafur 600 mg orally daily for two years
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: tegafur‐uracil 600 mg orally daily for two years
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: mitomycin C 20 mg intravenous bolus on the day of operation and 10 mg on the first postoperative day, plus mitomycin C 10 mg every three months for stage IV patients
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: histological curative resections
Number of subjects: 243
Study: 3133211

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (5-15 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30734104

Group type: EXPERIMENTAL
Intervention: 5 s MVC
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 5-15 s MVC and 6×5-MVC protocols
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 15-30 s repetitive MVC modalities and 15 electrical stimuli
Number of subjects: 120
Study: 27987231

Group type: EXPERIMENTAL
Intervention: Levodopa-entacapone-carbidopa intestinal gel after a 20% dose reduction
Number of subjects: 11

Group type: COMPARATOR
Intervention: Levodopa-carbidopa intestinal gel (usual dose)
Number of subjects: 11
Study: 26595801

Group type: EXPERIMENTAL
Intervention: PPROM with latency ≥4 weeks
Number of subjects: 1522

Group type: COMPARATOR
Intervention: PPROM with latency <4 weeks
Number of subjects: 1522
Study: 25812762

Group type: EXPERIMENTAL
Intervention: Best endovascular therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best open surgical treatment
Number of subjects: 0
Study: 23101952

Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Insulin aspart
Number of subjects: 20
Study: 19777109

Group type: EXPERIMENTAL
Intervention: 4-panel platform
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional video platform
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previous 2 examinations performance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCAT scores
Number of subjects: 0
Study: 17688757

Group type: EXPERIMENTAL
Intervention: Pain in the last 4 weeks
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Pain experience in the 'oldest old'
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Arthritis as a factor in pain reporting
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Impact of pain on activities of daily living
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Self-reported health status among those with pain
Number of subjects: 1090

Group type: EXPERIMENTAL
Intervention: Association between pain and depressed mood
Number of subjects: 1090
Study: 15465740

Group type: EXPERIMENTAL
Intervention: SFA-enriched diet (38% fat, 20% SFA)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: CHO-rich diet (30% fat, < 10% SFA, 55% carbohydrate)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: MUFA olive oil-rich diet (38% fat, 22% MUFA)
Number of subjects: 84
Study: 11802939

Group type: EXPERIMENTAL
Intervention: Mycobacterium vaccae vaccine (M. vaccae vaccine) with chemotherapy regimen of 2HRZE/2HR for 6 months
Number of subjects: 342

Group type: COMPARATOR
Intervention: Chemotherapy regimen of 2HRZE/4HR
Number of subjects: 342
Study: 9671334

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7809517

Group type: EXPERIMENTAL
Intervention: Percutaneous mitral balloon valvuloplasty (PMV)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mitral commissurotomy (MC)
Number of subjects: 80
Study: 2972790

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin
Number of subjects: 248

Group type: COMPARATOR
Intervention: Graduated compression stockings (TED stockings)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Both subcutaneous heparin and stockings
Number of subjects: 248
Study: 30406406

Group type: EXPERIMENTAL
Intervention: Anteromedial (AM) technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Transtibial (TT) technique
Number of subjects: 20
Study: 27535481

Group type: EXPERIMENTAL
Intervention: 100 mg oral micronized progesterone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 24894509

Group type: EXPERIMENTAL
Intervention: Expansion Plate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hyrax Expander
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 30
Study: 23841973

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 40
Study: 20667937

Group type: EXPERIMENTAL
Intervention: Niacin (1500 mg/day over 8 weeks, maintained for 12 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No additional treatment
Number of subjects: 15
Study: 18687278

Group type: EXPERIMENTAL
Intervention: Conservative treatment options for osteoarthritis, specific interventions not detailed.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional medical approach to management of OA, specific medications not detailed.
Number of subjects: 0
Study: 16192520

Group type: EXPERIMENTAL
Intervention: Propofol emulsion containing medium-chain triglyceride
Number of subjects: 130

Group type: COMPARATOR
Intervention: Lipid-free propofol
Number of subjects: 130
Study: 12897033

Group type: EXPERIMENTAL
Intervention: 6 microm albuterol aerosol at 20 microg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 3 microm albuterol aerosol at 20 microg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1.5 microm albuterol aerosol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 6 microm and 3 microm aerosols
Number of subjects: 18
Study: 10821987

Group type: EXPERIMENTAL
Intervention: Oral nalmefene 50 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Oral nalmefene 100 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Intravenous morphine 10 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Intravenous morphine 20 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Oral nalmefene 0 mg (placebo)
Number of subjects: 7
Study: 8644834

Group type: EXPERIMENTAL
Intervention: Kendall-Futuro #33 (Futuro)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: AliMed Freedom Short (AliMed Short)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Smith & Nephew Rolyan D‐Ring (Rolyan)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: LMB Wrist Rest (LMB)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: AliMed Freedom Long (AliMed Long)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Rolyan D‐Ring (Rolyan)
Number of subjects: 23
Study: 8444696

Group type: COMPARATOR
Intervention: Acute acetazolamide (500 mg iv)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Chronic acetazolamide (500 mg po every 6 h)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 5
Study: 3079687

Group type: EXPERIMENTAL
Intervention: 20% fat emulsion
Number of subjects: 16

Group type: COMPARATOR
Intervention: 10% fat emulsion
Number of subjects: 16
Study: 30902738

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (2 g per day of eicosapentaenoic acid (EPA) and 1 g of DHA)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 30138433

Group type: EXPERIMENTAL
Intervention: Collaborative care program for late-life depression
Number of subjects: 119

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 119
Study: 24359500

Group type: EXPERIMENTAL
Intervention: GSK239512 (10-20-40-80 µg)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196